Silexion Therapeutics* (NASDAQ: SLXN) is making strides in oncology with its RNAi-based treatment, SIL-204, targeting KRAS-driven cancers. In an interview on Market Leaders, CEO Ilan Hadar discussed the company’s recent breakthroughs and market activity.
During the interview, Hadar highlighted that SIL-204 has shown promising preclinical results, significantly reducing tumor growth in pancreatic cancer models through systemic administration. He emphasized that this advancement is critical in addressing metastatic cancers, a leading cause of patient mortality. With SIL-204 delivered through the bloodstream, it marks a major step forward in treating advanced-stage cancers, as most patients ultimately succumb to metastases rather than the primary tumor.
With regard to combination therapies, Hadar noted that Silexion’s research has shown SIL-204 works synergistically with established chemotherapies like gemcitabine and irinotecan, enhancing their effectiveness in preclinical models. Given that current pancreatic cancer treatments offer only marginal improvements in survival, he pointed out that this finding could significantly impact how these cancers are treated in the future.
Discussing the company’s market performance, Hadar acknowledged that Silexion has captured investor attention with a surge in trading activity. Over the past week, the company ranked among the most actively traded U.S. stocks, with Nasdaq data showing daily trading volumes of up to 400 million shares. He remarked that despite broader market fluctuations, Silexion’s momentum has remained strong, reflecting growing confidence in its pipeline and long-term vision.
Regarding capital raising efforts, Hadar explained that the company recently secured $3.3 million in gross proceeds through a warrant exercise, allowing investors to convert existing warrants early while issuing new ones at a higher strike price. He noted that this structure strengthens Silexion’s financial position without excessive dilution, ensuring the company remains well-funded as it progresses toward clinical trials.
Looking ahead, Hadar expressed confidence that with SIL-204 advancing toward human trials, Silexion is positioning itself as a leader in the fight against KRAS-driven cancers. He reiterated the company’s commitment to developing innovative therapies that could redefine treatment approaches for some of the most aggressive malignancies.
For listeners and industry professionals looking to stay updated, Silexion trades on the NASDAQ under SLXN, with more information available at www.silexion.com.
15 Day Chart – Silexion Therapeutics [as of Feb 2, 2024]
Subscribe for More Articles Like This
*Disclaimer: Nothing in this interview constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This interview is published and produced by Market Leaders, a research brand affiliated with the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to Silexion Therapeutics and was produced as part of their paid subscription to Wall Street Wire. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.